Global Breast Cancer Monoclonal Antibodies Market 2016-2020

Publisher Name :
Date: 06-Sep-2016
No. of pages: 88
Inquire Before Buying

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

The analysts forecast global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • Amgen

  • Roche

  • Mylan


Other prominent vendors


  • Array BioPharma

  • AstraZeneca

  • Biocad

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Celldex Therapeutics

  • Celltrion

  • Chugai Pharmaceutical

  • Daiichi Sankyo

  • DARA Biosciences

  • Eddingpharm

  • Eisai

  • Galena Biopharma

  • GlaxoSmithKline

  • Halozyme Therapeutics

  • Hospira

  • ImmunoGen

  • Immunomedics

  • MacroGenics

  • Merck

  • Novartis

  • Oncothyreon

  • Pfizer

  • ProStrakan

  • Puma Biotechnology

  • Seattle Genetics

  • Sun Pharmaceutical Industries

  • Synta Pharmaceuticals

  • Teva Pharmaceuticals


Market driver


  • Reimbursement benefits for breast cancer mAbs

  • For a full, detailed list, view our report


Market challenge


  • Absence of adequate diagnosis and screening procedures for early detection

  • For a full, detailed list, view our report


Market trend


  • Emergence of targeted and combination therapies for breast cancer

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Breast Cancer Monoclonal Antibodies Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Assumptions
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Breast cancer: Overview
Understanding the disease
Treatment regimen for breast cancer
Overview of mAbs

PART 06: Pipeline portfolio

PART 07: Market landscape
Market overview
Five forces analysis

PART 08: Market segmentation by type of mAbs
Naked mAbs
Conjugated mAbs

PART 09: Market segmentation by end-user
Hospitals
Retail pharmacies

PART 10: Geographical segmentation
Global breast cancer mAbs market by geographical segmentation 2015-2020
Breast cancer mAbs market in Americas
Breast cancer mAbs market in EMEA
Breast cancer mAbs market in APAC

PART 11: Market drivers
Reimbursement benefits for breast cancer mAbs
Increase in demand for breast cancer ADCs
Huge market potential for breast cancer mAbs owing to product approvals
Exposure to risk factors

PART 12: Impact of drivers

PART 13: Market challenges
Absence of adequate diagnosis and screening procedures for early detection
High manufacturing costs coupled with stringent regulations
Threat from chemotherapy and off-label drugs
Difficulties in patient recruitment for conducting clinical trials

PART 14: Impact of drivers and challenges

PART 15: Market trends
Emergence of targeted and combination therapies for breast cancer
Growing focus of vendors on untapped markets
Emergence of biosimilars
Outsourcing of biosimilar manufacturing activities
Need for high investment in R&D

PART 16: Vendor landscape
Competitive scenario
Key news
Roche
Amgen
Mylan
Other prominent vendors

PART 17: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global breast cancer mAbs market snapshot
Exhibit 03: Key buying criteria for breast cancer mAbs 2015
Exhibit 04: Impact of key customer segments on market 2015
Exhibit 05: Breast cancer stages based on tumor size and extent of metastasis
Exhibit 06: Classification of breast cancer based on genetic make-up of tumor cells
Exhibit 07: Treatment regimen for breast cancer
Exhibit 08: Comparison of small molecules and mAbs
Exhibit 09: Preparation of mAbs
Exhibit 10: Global breast cancer mAbs market: Key metrics analysis snapshot
Exhibit 11: Global breast cancer mAbs market: Pipeline snapshot 2015
Exhibit 12: Pipeline portfolio: Global breast cancer mAbs market 2015
Exhibit 13: Developmental history of trastuzumab biosimilars in various countries
Exhibit 14: Global breast cancer mAbs market snapshot: Developed and emerging markets 2015
Exhibit 15: Global breast cancer mAbs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global breast cancer mAbs market 2015
Exhibit 17: Timeline for development of breast cancer mAbs
Exhibit 18: Impact of drivers and challenges of global breast cancer mAbs market
Exhibit 19: Five forces analysis
Exhibit 20: Approved naked mAbs by US FDA and EU
Exhibit 21: Global breast cancer mAbs market segmentation by type of molecule 2015
Exhibit 22: Global breast cancer mAbs market segmentation by end-user 2015
Exhibit 23: Global breast cancer mAbs market: Geographical outlook 2015-2020
Exhibit 24: Global breast cancer mAbs market: Geographical outlook 2015
Exhibit 25: Revenue/growth outlook in different countries/regions 2015
Exhibit 26: Global breast cancer mAbs market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 27: Opportunity analysis of breast cancer mAbs market in Americas
Exhibit 28: Breast cancer mAbs market in Americas 2015-2020 ($ billions)
Exhibit 29: Breast cancer mAbs market in Americas by country 2015
Exhibit 30: Opportunity analysis of breast cancer mAbs market in EMEA
Exhibit 31: Breast cancer mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 32: Opportunity analysis of breast cancer mAbs market in APAC
Exhibit 33: Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
Exhibit 34: Breast cancer mAbs market in APAC 2015-2020 ($ billions)
Exhibit 35: Global breast cancer mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 36: Impact of drivers
Exhibit 37: Five-year survival rate by stage of diagnosis
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Global breast cancer mAbs market: Impact assessment of key trends
Exhibit 40: Competitive assessment of vendors
Exhibit 41: Key vendors: Geographical presence 2015
Exhibit 42: Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 43: Roche: Geographical segmentation of Avastin by revenue 2015
Exhibit 44: Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 45: Roche: Geographical segmentation of Herceptin 2015
Exhibit 46: Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 47: Roche: Geographical segmentation of Perjeta 2015
Exhibit 48: Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 49: Roche: Geographical segmentation of Kadcyla 2015
Exhibit 50: Roche: Metrics analysis
Exhibit 51: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 52: Amgen: Geographical segmentation of Xgeva 2015
Exhibit 53: Amgen: Metrics analysis
Exhibit 54: Mylan: Business segmentation by revenue 2015
Exhibit 55: Mylan: Geographical segmentation by revenue 2015 (generics segment)
Exhibit 56: Mylan: Metrics analysis

  • Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023
    Published: 24-Mar-2017        Price: US 4950 Onwards        Pages: 132
    Summary DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics mar......
  • Oral Mucositis - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 91
    Oral Mucositis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape. Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the inte......
  • Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 88
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, dr......
  • Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 107
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and ab......
  • Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017
    Published: 01-Mar-2017        Price: US 2450 Onwards        Pages: 90
    DelveInsight's, "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrog......
  • Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017
    Published: 01-Mar-2017        Price: US 2450 Onwards        Pages: 90
    DelveInsight's, "Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017", report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the ovarian cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Ovarian Cancer which mainly describes the treatment of ovarian cancer ......
  • Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017
    Published: 01-Mar-2017        Price: US 2750 Onwards        Pages: 365
    DelveInsight's, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen ......
  • Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 470
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Personalized Medicine in Oncology Partneri......
  • Global Mucositis Partnering 2010-2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the mucositis partnering deals and agreements entered into by the worlds leading healthcare companies Description The Global Mucositis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs